--- title: "Advanced Melanoma Ignyte-3 | Sutter Health" description: "Randomized, Ph3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination With Nivolumab Vs Treatment of Physician's Choice in Patients With Advanced Melanoma That Progressed on Anti-PD-1 and Anti-CTLA-4 Containing Treatment" url: "https://www.sutterhealth.org/research/clinical-trials/advanced-melanoma-ignyte-3-1095539355" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. Advanced Melanoma Ignyte-3 # Advanced Melanoma Ignyte-3 **Status:** Open to Enrollment [Email us to enroll](https://www.sutterhealth.org/research/clinical-trials/advanced-melanoma-ignyte-3-1095539355#enroll) #### Study details View study details on [www.clinicaltrials.gov](https://www.clinicaltrials.gov/study/NCT06264180?term=NCT06264180&rank=1). #### Locations - San Francisco #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3). This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage IIIb-IV cutaneous melanoma whose disease progressed on an anti PD-1 and an anti-CTLA-4 containing regimen (administered either as a combination regimen or in sequence) or who are not candidates for treatment with an anti-CTLA-4 therapy. ![Kevin B Kim, M.D.](https://dyn.mktgcdn.com/p/c5YP2PezO8WGhQo-AyMNM4jgZenkBbfA9R6zjGEliTY/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Kevin B Kim, M.D. Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/kevin-b-kim-md-1049681162) ![Dron Gauchan, M.D.](https://dyn.mktgcdn.com/p/0fCyS_704YpY2A8viqU-BukeGy4TDdCv0qxgxLEceLs/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Dron Gauchan, M.D. Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/dron-gauchan-md-1049681200) ## Sub-Investigators [Nitin Rohatgi, M.D., MBA](https://www.sutterhealth.org/research/investigators/nitin-rohatgi-md-mba-1049681017) , [Benjamin G Coombs, D.O.](https://www.sutterhealth.org/research/investigators/benjamin-g-coombs-do-1049681247) , [Christopher J Laing, M.D.](https://www.sutterhealth.org/research/investigators/christopher-j-laing-md-1049681135) , [Henal H Patel, M.D.](https://www.sutterhealth.org/research/investigators/henal-h-patel-md-1049681250) , [Aria Sasaki, M.D.](https://www.sutterhealth.org/research/investigators/aria-sasaki-md-1049681251) ## Email us to enroll - [Email San Francisco](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Advanced%20Melanoma%20Ignyte-3%20in%20San%20Francisco&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [Advanced Melanoma Mirdametinib CPMC24-MEL01](https://www.sutterhealth.org/research/clinical-trials/advanced-melanoma-mirdametinib-cpmc24-mel01-2036974828) A Pilot Study of Mirdametinib in Patients With Advanced Melanoma With an NF1 Mutation (CPMC24-MEL01) **Status:** Open to Enrollment - Clinical trial ### [Advanced Cervical Cancer NRG GY037](https://www.sutterhealth.org/research/clinical-trials/advanced-cervical-cancer-nrg-gy037-2097344123) A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer **Status:** Open to Enrollment - Clinical trial ### [Advanced Staged Cancer Targeted Therapy ASCO TAPUR](https://www.sutterhealth.org/research/clinical-trials/targeted-agent-and-profiling-utilization-registry-tapur-st-1049141787) Targeted Agent and Profiling Utilization Registry (TAPUR) Study **Status:** Open to Enrollment - Clinical trial ### [Adverse Effects of Chemotherapy Shengbai Solution](https://www.sutterhealth.org/research/clinical-trials/adverse-effects-of-chemotherapy-shengbai-solution-1097505286) A Randomized, Blinded, Placebo-controlled Trial of Shengbai Oral Formula to Assess Safety and Alleviation of Adverse Effects in Patients With Cancer Undergoing Chemotherapy **Status:** Open to Enrollment - Clinical trial ### [Acute Myeloid Leukemia Dental Wipes COG ACCL2531](https://www.sutterhealth.org/research/clinical-trials/acute-myeloid-leukemia-dental-wipes-cog-accl2531-2099128841) A Randomized Double-Blinded Trial of Xylitol Dental Wipes for the Prophylaxis of Bloodstream Infections From Oral Organisms in Pediatric Patients With Acute Myeloid Leukemia **Status:** Open to Enrollment [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/advanced-melanoma-ignyte-3-1095539355#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Advanced Melanoma Ignyte-3"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/advanced-melanoma-ignyte-3-1095539355#medicalwebpage","name":"Advanced Melanoma Ignyte-3","description":"Randomized, Ph3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination With Nivolumab Vs Treatment of Physician's Choice in Patients With Advanced Melanoma That Progressed on Anti-PD-1 and Anti-CTLA-4 Containing Treatment","url":"https://www.sutterhealth.org/research/clinical-trials/advanced-melanoma-ignyte-3-1095539355","inLanguage":"en-US","dateModified":"2026-06-02","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/advanced-melanoma-ignyte-3-1095539355#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/advanced-melanoma-ignyte-3-1095539355#breadcrumblist"},"mentions":[{"@type":"Person","name":"Kevin B Kim, M.D.","url":"https://www.sutterhealth.org/research/investigators/kevin-b-kim-md-1049681162","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}},{"@type":"Person","name":"Dron Gauchan, M.D.","url":"https://www.sutterhealth.org/research/investigators/dron-gauchan-md-1049681200","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/advanced-melanoma-ignyte-3-1095539355#medicaltrial","name":"Advanced Melanoma Ignyte-3","alternateName":"Randomized, Ph3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination With Nivolumab Vs Treatment of Physician's Choice in Patients With Advanced Melanoma That Progressed on Anti-PD-1 and Anti-CTLA-4 Containing Treatment","url":"https://www.sutterhealth.org/research/clinical-trials/advanced-melanoma-ignyte-3-1095539355","description":"VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3). This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage IIIb-IV cutaneous melanoma whose disease progressed on an anti PD-1 and an anti-CTLA-4 containing regimen (administered either as a combination regimen or in sequence) or who are not candidates for treatment with an anti-CTLA-4 therapy.","identifier":"NCT06264180","code":{"@type":"MedicalCode","codeValue":"NCT06264180","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://www.clinicaltrials.gov/study/NCT06264180?term=NCT06264180&rank=1","status":"https://schema.org/Recruiting","healthCondition":[{"@type":"MedicalCondition","name":"Skin Cancer/Melanoma"}],"studyLocation":[{"@type":"AdministrativeArea","name":"San Francisco"}]} ```